US3856820A - 2-AMINOMETHYL DIBENZO (b,d) PYRANS - Google Patents

2-AMINOMETHYL DIBENZO (b,d) PYRANS Download PDF

Info

Publication number
US3856820A
US3856820A US00380326A US38032673A US3856820A US 3856820 A US3856820 A US 3856820A US 00380326 A US00380326 A US 00380326A US 38032673 A US38032673 A US 38032673A US 3856820 A US3856820 A US 3856820A
Authority
US
United States
Prior art keywords
dibenzo
pyran
hydroxy
trimethyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00380326A
Inventor
B Loev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Corp filed Critical SmithKline Corp
Priority to US00380326A priority Critical patent/US3856820A/en
Application granted granted Critical
Publication of US3856820A publication Critical patent/US3856820A/en
Assigned to SMITHKLINE BECKMAN CORPORATION reassignment SMITHKLINE BECKMAN CORPORATION CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). EFFECTIVE DATE: 03/04/82 Assignors: SMITHKLINE CORPORATION
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C07C43/2055Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides

Definitions

  • Advantageous compounds of this invention are rep- 1 resented by Formula I in which ring A is a cyclohexene OR CH l ring with the double bond at position 6al0a, R is R 2 2 ⁇ R methyl in the 9-position, R is hydrogen or acetyl, R is 1 5 10 a saturated hydrocarbon chain optionally branched R with from one to three methyl groups, with R contain- 3 ing a total of from five to twelve carbon atoms and R R and R are methyl.
  • ring A is a benzene ring, a cyclohexane ring or a cy- C1ii clohexene ring with the double bond being at posi- CH 0H CH N tion 6a-10a, 8, or 9;
  • CH R is hydrogen, methyl or ethyl;
  • (CH CH R is hydrogen or lower alkanoyl of from two to five I 2 4 3 carbon atoms;
  • 3 3 R is a saturated hydrocarbon chain optionally branched with from one to three alkyl groups, each CH CH group consisting of one or two carbon atoms, with 3 3 illciosntammg a total of from five to twelve carbon FORMULA H R4 an R5 a hydr g n or lower a yl of r n to
  • the compounds of this invention may exist as optical our carbon a ms or a j i d g t w t isomers due to the possible asymmetry of carbon
  • drogen are obtained by Mannich condensations on 3- alkyl-l-hydroxy-6-H-dibenzo[b,d]pyrans according to standard procedures, for example, by reaction of a 3- alkyl-l-hydroxy-6H-dibenzo[b,d]pyran with formaldehyde and an amine of the formula R R NH in a solvent such as ethanol at a temperature of from about 25 to 80 as shown in the following scheme:
  • R R R R R and A are defined as desentcd by Formula I in which ring A is a cyclobexene scribed above.
  • the corresponding compounds of Formula 1 in which R is hydrogen may be prepared by condensation of a 3- alkyl-l-hydroxy-6H-dibenzo[b,d]pyran with an N-alkyl-N-benzylamine and formaldehyde as described above followed by chemical or catalytic debenzylation, for example by the use of sodium in liquid ammonium or by hydrogenolysis over palladium on carbon in glacial acetic acid, to give the 3-alkyl-2-(N-alkylaminomethyl)-1-hydroxy-6H-dibenzo[b,d]pyran.
  • R, and R are hydrogen
  • the corresponding compounds of Formula 1 in which R is hydrogen may be prepared by condensation of a 3-alkyl-lhydroxy-6H-dibenzo[b,dlpyran with dibenzylamine and formaldehyde followed by debenzylation as described above.
  • the 3-alkyl-1-hydroxy-6l-l-dibenzo[b,d]pyrans in which ring A is a cyclohexene ring with the double bond at position 6a-10a and R is hydrogen are prepared by condensation of a 2-carbalkoxycyclohexanone, for example 2-carbethoxycyclohexanone with a 5-alkyl resorcinol followed by treatment of the 3-alkyll-hydroxy-7,8,9,10-tetrahydro-6H- dibenzo[b,d]pyrone with a methyl or ethyl magnesium halide and subsequent cyclization to the 3-a1kyl-1- hydroxy-7,8,9,10-tetrahydro-6I-l-dibenzo[b,d]pyran by addition of the reaction mixture to aqueous acid, for example dilute hydrochloric acid.
  • aqueous acid for example dilute hydrochloric acid.
  • the 3-alkyl-1 -hydroxy-6a, 7,10,10a-tetrahydro-6I-ldibenzo[b,d]pyrans, in which ring A is a cyclohexene ring with the double bond at the 8-position and R is hydrogen, are prepared by condensing verbenol or an analog thereof with a 5-alkyl resorcinol in the presence of acid such as p-toluenesulfonic acid followed by treatment of the resulting adduct with boron trifluoride etherate by the procedure of Mechoulam et a1. [Arzneim.- Forsch. 2221995 (1972)] as shown in the following scheme:
  • the alkyl substituted resorcinols are prepared from reaction of 3,5-dimethoxyacetophenone, 3,5-dimethoxybenzaldehyde or 3,S-dimethoxybenzonitrile with an appropriate alkyl magnesium halide with subsequent dehydration of the intermediate alcohols followed by hydrogenation and removal of the protective groups by standard procedures, for example by acid hydrolysis or with pyridine hydrochloride or boron tribromide.
  • the 3-alkyl-1-hydroxy-6H-dibenzo[b,d]pyrans in which ring A is benzene ring and R is hydrogen are prepared by dehydrogenation of the corresponding compounds in which ring A is a cyclohexene ring.
  • the dehydrogenation is carried out either using a catalyst such as palladium on carbon or using a chemical dehydrogenating agent such as 2,3-dichloro-5,6- dicyanoquinone.
  • R is hydrogen by conventional methods, for example by reacting the hydroxy compound anti-inflammatory and diuretic activity.
  • the central nervous system activity is demonstrated by oral administration to rats at doses of about 50 to 100 mg./kg. to produce effects such as decreased spontaneous motor activity.
  • the compounds of this invention may be combined with standard pharmaceutical carriers and administered internally in conventional dosage forms such as capsules, tablets or liquid preparations.
  • the title compound is prepared by substitution of an equivalent amount of N-methyl-N- benzylamine in the procedure of Example 1 for dimethylamine followed by hydrogenolysis of the resulting 3- (1,2-dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro- 2-(N-methyl-N-benzylaminomethyl)-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran over palladium on carbon in glacial acetic acid.
  • the title compound is also prepared by substitution of an equivalent amount of dibenzylamine in the alternate procedure of Example 3 for N-methyl-N- benzylamine.
  • the aromatized dibenzo[b,d]pyran may be obtained from 3-(l,2-dimethylheptyl)-1- hydroxy-6a, 7,8,l0a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran or from 3-(1,2-dimethylheptyl)-lhydroxy-6a, 7,10,l0a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
  • EXAMPLE 8 2-(N,N-Dimethylaminomethyl)-3-(1.2-dimethylheptyl)-l-hydroxy-6a, 7,8,9,10,l0a-hexahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran
  • the hexahydro dibenzo[b,d]pyran may be obtained from 3-(1,2-dimethylheptyl)-1- hydroxy-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran or from 3-(1,2-dimethylheptyl)-lhydroxy-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
  • the layers are separated and the organic phase is washed with 5 percent aqueous sodium bicarbonate, dried (MgSO and concentrated. The residue is triturated with a minimum amount of 40 percent aqueous sodium hydroxide. The precipitate which forms is filtered, washed with benzene and percent aqueous sodium hydroxide, acidified with dilute hydrochloric acid and extracted into benzene. The benzene solution is dried (MgSO and concentrated to give 3- 1 ,2-dimethyldecyl)-l-hydroxy-7,8,9,10-tetrahydro-9- methyl-6l-l-dibenzo[b,d]pyrone.
  • EXAMPLE 18 When equivalent amounts of l,2-dimethylheptyl)- resorcinol and 4-methyl-2-carbethoxycyclohexanone are condensed according to the procedure described in Example 9 and the intermediate dibenzo[b,d]pyrone is treated with methyl magnesium bromide and the product cyclized, 3-(l,2-dimethylheptyl)-l-hydroxy- 7,8,9,lO-tetrahydro-6,6,8-trimethyl-6ll-ldibenzo[b,d]pyran is obtained.
  • EXAMPLE 32 3-(1,2-Dimethylheptyl)-l-hydroxy-2-(N- methylaminomethyl)-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran is prepared by substitution of an equivalent amount of 3-( l,2-dimethylheptyl)-lhydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 3 for 3-(l,2-dimethylheptyl)-lhydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
  • EXAMPLE 36 By the procedure of Example 35, using propionic anhydride in place of acetic anhydride, the product is 2- (N,N-dimeth-ylaminomethyl)-3-( 1 ,Z-dimethylheptyl 7,8,9,10-tetrahydro-6,6,9-trimethyl-1-propionyloxy- 6H-dibenzo[b,d]pyran.
  • the product is l-n-butyryloxy-2-(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-7,8,9,l0-tetrahydro-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran.
  • ring A is a benzene ring, a cyclohexane ring or a cyclohexene ring with the double bond being at position 6a-10a, 8 or 9;
  • R is hydrogen, methyl or ethyl
  • R is hydrogen or lower alkanoyl of from two to five carbon atoms
  • R is a saturated hydrocarbon chain optionally branched with from one to three alkyl groups, each group consisting of one or two carbon atoms, with R containing a total of from five to twelve carbon atoms;
  • R; and R are hydrogen or lower alkyl of from one to four carbon atoms or are joined together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine ring;
  • R is methyl or ethyl.
  • ring A is a cyclohexene ring with the double bond at the 6a-l0a position and R and R are lower alkyl of from one to four carbon atoms or are joined together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine ring.
  • R is methyl in the 9-position
  • R is hydrogen or acetyl
  • R is a saturated hydrocarbon chain optionally branched with from one to three methyl groups, with R containing a total of from five to twelve carbon atoms and R R and R are methyl.
  • a compound as claimed in claim 3 being the compound 2(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-1-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The compounds of this invention are 2-aminomethyl dibenzo(b, d)pyrans having pharmacological activity such as central nervous system activity. A preferred compound of this invention is 2-(N, N-dimethylaminomethyl)-3-(1,2-dimethylheptyl)-1-hydroxy-7,8,9,10tetrahydro -6,6,9-trimethyl-6H-dibenzo(b,d)pyran.

Description

Wire States iLnev atent [1 1 Dec. 24, W74
[ Z-AMINOMETHYL DIBENZO (b,d) PYRANS [75] Inventor:
[73] Assignee: Smith Kline Corporation,
Philadelphia, Pa.
[22] Filed: July 18, 1973 [21] Appl. No.: 380,326
Bernard Loev, Broomall, Pa.
[52] US. Cl..... 260/345.3, 424/283, 260/326.5 CA,
260/293.58 [51] Int. Cl C07d 7/20 [58] Field of Search... 260/345.3, 326.5 CA, 293.58
[56] References Cited UNITED STATES PATENTS 3,654,312 4/1972 Pars et all 260/3453 Primary ExaminerJ0hn M. Ford Attorney, Agent, or Firm-J0an S. Keps; Richard D. Foggio; William H. Edgerton [57] ABSTRACT 4 Claims, N0 Drawings l 2 Z-AMllNOMlETHYL DIBENZO [b,d] PYRANS ring with the double bond at the 6a-10a position and R and R are lower alkyl of from one to four carbon This invention relates to new 2-aminomethyl dibenatoms or are joined together with the nitrogen atom to zo[b,d]pyrans which have pharmacological activity. which they are attached to form a piperidine or a pyr- The compounds of this invention are represented by 5 rolidine ring. the following structural formula: Advantageous compounds of this invention are rep- 1 resented by Formula I in which ring A is a cyclohexene OR CH l ring with the double bond at position 6al0a, R is R 2 2 \R methyl in the 9-position, R is hydrogen or acetyl, R is 1 5 10 a saturated hydrocarbon chain optionally branched R with from one to three methyl groups, with R contain- 3 ing a total of from five to twelve carbon atoms and R R and R are methyl. 0 Particularly preferred is the compound 2-N,N- R R dimethylaminomethyl)-3-(l,2-dimethylheptyl)-lhydroxy-7,8,9,lO-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran. This compound is represented by FORMULA I the following structural formula: in which:
ring A is a benzene ring, a cyclohexane ring or a cy- C1ii clohexene ring with the double bond being at posi- CH 0H CH N tion 6a-10a, 8, or 9; CH R is hydrogen, methyl or ethyl; (CH CH R is hydrogen or lower alkanoyl of from two to five I 2 4 3 carbon atoms; 3 3 R is a saturated hydrocarbon chain optionally branched with from one to three alkyl groups, each CH CH group consisting of one or two carbon atoms, with 3 3 illciosntammg a total of from five to twelve carbon FORMULA H R4 an R5 a hydr g n or lower a yl of r n to The compounds of this invention may exist as optical our carbon a ms or a j i d g t w t isomers due to the possible asymmetry of carbon atoms nitrogen atom to which they are attach to m in the side chain and in ring A. All of the isomers, in-
piperidine Of a Pyrmlidine g; and cluding separated isomers and mixtures thereof, are ine is methyl or ethyl. cluded within the scope of this invention. In the nomenclature Used herein the l lpy- The compounds of this invention in which R is hyg is numbered as follows? drogen are obtained by Mannich condensations on 3- alkyl-l-hydroxy-6-H-dibenzo[b,d]pyrans according to standard procedures, for example, by reaction of a 3- alkyl-l-hydroxy-6H-dibenzo[b,d]pyran with formaldehyde and an amine of the formula R R NH in a solvent such as ethanol at a temperature of from about 25 to 80 as shown in the following scheme:
Preferred compounds of this invention are repre- The terms R R R R R and A are defined as desentcd by Formula I in which ring A is a cyclobexene scribed above.
Alternatively, when one of R or R is hydrogen the corresponding compounds of Formula 1 in which R is hydrogen may be prepared by condensation of a 3- alkyl-l-hydroxy-6H-dibenzo[b,d]pyran with an N-alkyl-N-benzylamine and formaldehyde as described above followed by chemical or catalytic debenzylation, for example by the use of sodium in liquid ammonium or by hydrogenolysis over palladium on carbon in glacial acetic acid, to give the 3-alkyl-2-(N-alkylaminomethyl)-1-hydroxy-6H-dibenzo[b,d]pyran.
When both R, and R are hydrogen the corresponding compounds of Formula 1 in which R is hydrogen may be prepared by condensation of a 3-alkyl-lhydroxy-6H-dibenzo[b,dlpyran with dibenzylamine and formaldehyde followed by debenzylation as described above.
The 3-alkyl-l-hydroxy-6H-dibenzo[b,d]pyran starting materials in the above procedure are prepared as follows.
The 3-alkyl-1-hydroxy-6l-l-dibenzo[b,d]pyrans in which ring A is a cyclohexene ring with the double bond at position 6a-10a and R is hydrogen are prepared by condensation of a 2-carbalkoxycyclohexanone, for example 2-carbethoxycyclohexanone with a 5-alkyl resorcinol followed by treatment of the 3-alkyll-hydroxy-7,8,9,10-tetrahydro-6H- dibenzo[b,d]pyrone with a methyl or ethyl magnesium halide and subsequent cyclization to the 3-a1kyl-1- hydroxy-7,8,9,10-tetrahydro-6I-l-dibenzo[b,d]pyran by addition of the reaction mixture to aqueous acid, for example dilute hydrochloric acid.
The 3-alkyl-1 -hydroxy-6a, 7,10,10a-tetrahydro-6I-ldibenzo[b,d]pyrans, in which ring A is a cyclohexene ring with the double bond at the 8-position and R is hydrogen, are prepared by condensing verbenol or an analog thereof with a 5-alkyl resorcinol in the presence of acid such as p-toluenesulfonic acid followed by treatment of the resulting adduct with boron trifluoride etherate by the procedure of Mechoulam et a1. [Arzneim.- Forsch. 2221995 (1972)] as shown in the following scheme:
R R6 Q on HO R6 The 3-alkyl-l-hydroxy-6a, 7,8,lOa-tetrahydro-6H- dibenzo[b,d]pyrans, where ring A is a cyclohexene ring with the double bond at the 9-position and R is hydrogen, are prepared by isomerization of the corresponding 3-alkyl-l-hydroxy-6a, 7,10,10a-tetrahydro-6H- dibenzo[b',d]pyrans with zinc chloride and hydrogen chloride followed by treatment with base [Mechoulam et al., Arzneim.-Forsch. 22:1995 (1972) and Petrzilka et al., Helv. Chim. Acta 52:1102 (1969)].
Other procedures which may be applied to prepare the 3-alkyl-l-hydroxy-6a, 7,8,l0a-tetrahydro-6H- dibenzo[b,d]pyrans are described by Fahrenholtz et al., J. Amer. Chem. Soc. 89:5934 (1967), Mechoulam et al., J. Amer. Chem. Soc. 8924552 (1967) and Razdan et al., J. Amer. Chem. Soc. 9216061 (1970) and in U.S. Pat. No. 3,388,136.
The alkyl substituted resorcinols are prepared from reaction of 3,5-dimethoxyacetophenone, 3,5-dimethoxybenzaldehyde or 3,S-dimethoxybenzonitrile with an appropriate alkyl magnesium halide with subsequent dehydration of the intermediate alcohols followed by hydrogenation and removal of the protective groups by standard procedures, for example by acid hydrolysis or with pyridine hydrochloride or boron tribromide.
The 3-alkyl-1-hydroxy-6H-dibenzo[b,d]pyrans in which ring A is benzene ring and R is hydrogen are prepared by dehydrogenation of the corresponding compounds in which ring A is a cyclohexene ring. The dehydrogenation is carried out either using a catalyst such as palladium on carbon or using a chemical dehydrogenating agent such as 2,3-dichloro-5,6- dicyanoquinone.
The 3-alkyl-1-hydroxy-6a, 7,8,9,10,l0a-hexahydro- 6H-dibenzo[b,d]pyrans, in which ring A is a cyclohexane ring and R is hydrogen are prepared from the corresponding compounds in which ring A is a cyclohexene ring by chemical or catalytic reduction according to standard procedures such as with palladium on carbon in ethanol.
The compounds of Formula I in which R is lower alkanoyl are prepared from the corresponding com- R R1 on 1 on BF .0Et R R 3 R on o 6 a The terms R R and R are defined as described above.
pounds in which R is hydrogen by conventional methods, for example by reacting the hydroxy compound anti-inflammatory and diuretic activity.
The central nervous system activity is demonstrated by oral administration to rats at doses of about 50 to 100 mg./kg. to produce effects such as decreased spontaneous motor activity.
One skilled in the art will recognize that in determining the amounts of the compound to produce the desired pharmacological effect, the activity of the compound as well as the size of the host animal must be considered.
The compounds of this invention may be combined with standard pharmaceutical carriers and administered internally in conventional dosage forms such as capsules, tablets or liquid preparations.
The following examples illustrate the invention but are not to be construed as limiting the scope thereof. Temperatures are in degrees Centigrade unless otherwise stated.
EXAMPLE 1 2-(N,N-Dimethylaminomethyl)-3-(1,2- dimethylheptyl)-l -hydroxy-7,8,9, 1 0-tetrahydro-6,6,9- trimethyl-6l-l-dibenzo[b,d]pyran To a warm solution of 10.1 g. (0.027 mol.) of 3-(1,2- dimethylheptyl)-l-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,dlpyran in 75 ml. of ethanol was added 1.8 g. (0.060 mol.) of paraformaldehyde, 7 ml. (0.060 mol.) of 40 percent aqueous dimethylamine and 10 drops of acetic acid. The solution was refluxed for 45 minutes and allowed to stir at for 18 hours. The colorless precipitate was filtered, washed with cold methanol and recrystallized from anhydrous methanol to give the title compound, m.p. l03107.
EXAMPLE 2 Substitution of an equivalent amount of an amine listed below:
diethylamine methyl ethyl amine diisopropylamine di-n-butylamine pyrrolidine piperidine into the procedure of Example 1 for dimethylamine gives the following Z-aminomethyl dibenzo[b,d]pyrans, respectively:
2-(N,N-diethylaminomethyl)-3-(1,2-
dimethylheptyl)-l-hydroxy-7,8,9, lO-tetrahydro- 6,6,9-trimethyl-6Hdibenzo[b,d]pyran 3-(1,Z-dimethylheptyl)-2-(N-ethyl-N- methylaminomethyl)-l-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran 2-(N,N-diisopropylaminomethyl)-3- (1,2dimethylheptyl)-l-hydroxy-7,8,9, l0- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran 2-(N,N-di-n-butylaminomethyl)-3-(1,2-
dimethylheptyl)-1-hydroxy-7,8,9,IO-tetrahydro- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran 3-( 1 ,2-dimethylheptyl)-1-hydroxy-7,8,9,10-
tetrahydro-6,6,9-trimethyl-2-pyrrolidinomethyl- 6H-dibenzo[b,d]pyran 3( l,2-dimethylheptyl)-1-hydroxy-7,8,9,l0-
tetrahy dro-o,0,9-trimethyl-2-piperidinomethyl-6l-ldibenzo[b,d]pyran.
EXAMPLE 3 3-(1,2-Dimethylheptyl)-l-hydroxy-7,8,9,10- tetrahydro-Z-(N-methylaminomethyl)-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran When an equivalent amount of 40 percent aqueous methyl amine is substituted in the procedure of Example 1 for dimethylamine, the title compound is formed. After stirring at 25, 200 ml. of water is added to the reaction mixture and the resulting solution is extracted with ether. The extracts are dried (MgSO and saturated with gaseous hydrogen chloride. The precipitated gum is collected and washed with dry ether, then stirred with ml. of 10 percent aqueous sodium carbonate and 100 m1. of ether. The etheral solution is washed with water, dried (MgSO and concentrated to give the title compound.
Alternatively, the title compound is prepared by substitution of an equivalent amount of N-methyl-N- benzylamine in the procedure of Example 1 for dimethylamine followed by hydrogenolysis of the resulting 3- (1,2-dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro- 2-(N-methyl-N-benzylaminomethyl)-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran over palladium on carbon in glacial acetic acid.
EXAMPLE 4 2-Aminomethyl-3-( l ,2-dimethylheptyl)- 1 -hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]py'ran When an equivalent amount of aqueous ammonia is substituted in the procedure of Example 3 for methyl amine, the title compound is obtained.
The title compound is also prepared by substitution of an equivalent amount of dibenzylamine in the alternate procedure of Example 3 for N-methyl-N- benzylamine.
EXAMPLE 5 2-(N,N-Dimethylaminomethyl)-3-(1,2-dimethylheptyl)-1 -hy droxy- 6a 7,10,10a-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,dlpyran To a stirred solution of 0.23 g. (1.4 mmol.) of dry p-toluenesulfonic acid and 2.4 g. (10 mmol.) of 5-( l ,2- dimethylheptyl)resorcinol in 500 ml. of chloroform is added a solution of 1.9 g. (13.5 mmol.) of cis-verbenol [J. Chem. Soc. 2864 (1960)] in 200 ml. of chloroform over a 50 minute interval. The reaction mixture is stirred for 30 minutes, then ether and water are added and the layers are separated. The organic phase is washed with 5 percent aqueous sodium bicarbonate, dried (MgSO and concentrated in vacuo. The residue is chromatographed on Florisil and eluted with 5 percent ether-petroleum ether to give 2,6-dihydroxy-4- (l,2-dimethylheptyl)-l-verbenylbenzene which is dissolved in 100 ml. of methylene chloride containing 1 ml. of boron trifluoride etherate. After 30 minutes ether and water are added and the layers are separated. The aqueous phase is extracted twice with ether and the combined extracts are washed with 5 percent aqueous sodium bicarbonate, dried (MgSO and concentrated in vacuo. Chromatography of the residue on Florisil and elution with 2 percent etherpetroleum ether gives 3-([ ,2dimethylheptyl)-I-hydrxy-6a,7, 10,
10a-tetrahydro-6,6.9-trimethyl-6H- dibenzo[b,d]pyran.
When an equivalent amount of 3-(1,2-dimethyl-heptyl)-1-hydroxy-6a, 7,10,10a-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran is substituted in the procedure of Example 1 for 3-(1,2-dimethylheptyl)-1- hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran, the title compound is obtained.
' EXAMPLE 6 2-(N,N-Dimethylaminomethyl)-3-(1,2-dimethylheptyl)-l-hydroxy-6a, 7,8,l0a-tetrahydro-6,6,9-trimethyl- 6l-l-dibenzo[b,d]pyran Dry gaseous hydrogen chloride is bubbled into a solution of 4.6 g. (13 mmol.) of 3-(1,2-dimethylheptyl)-lhydroxy-6a, 7,10,10a-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran in 250 ml. of dry toluene containing 0.5 g. (3.7 mmol.) of anhydrous zinc chloride at to 15 for six hours. The reaction mixture is filtered and the filtrate is washed with water until neutral, dried (MgSO and concentrated in vacuo at 25. The residue is dried for 12 hours at 25 under vacuum to give 9-chloro-3-(1,2-dimethylheptyl)-1-hydroxy-6a, 7,8,10,
a-pentahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
To a 1M solution of potassium t-amylate in 10 ml. of benzene under an argon atmosphere at 5 is added dropwise with stirring a solution of 3.1 mmol. of the 9-chloro-6H-dibenzo[b,d]pyran in ml. of dry benzene. The reaction mixture is heated to 65 for 15 minutes, then it is cooled in an ice bath and bubbled with carbon dioxide for 30 minutes. Ether and ice water are added and the mixture is neutralized with 5 percent aqueous sodium bicarbonate. The layers are separated and the organic phase is dried (MgSO and concentrated in vacuo to give 3-(1,2-dimethylheptyl)-lhydroxy-6a, 7,8,10a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
When an equivalent amount of 3-(1,2-dimethylheptyl)-l-hydroxy-6a, 7,8,l0a-tetrahydro-6,6,9-trimethyloil-dibenzo[b,d]pyran is substituted in'the procedure of Example 1 for 3-(l,2-dimethylheptyl)-l-hydroxy- 7,8 ,9, 1 0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran, the title compound is obtained.
EXAMPLE 7 2-(N,N-Dimethylaminomethyl)-3-( l ,2- dimethylheptyl)-l-hydroxy-6,6,9-trimethyl-6H- dibenzo[b,d]pyran A solution of 200 g. of 3-(1,2-dimethylheptyl)-1- hydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo-[b,d]pyran in 70 ml. ofdry p-cymene is added dropwise at reflux to a well stirred suspension of 660 mg. of 10 percent palladium on carbon in 70 ml. of dry p-cymene, which is bubbled continuously with nitrogen. The addition is made over 45 minutes Refluxing is continued for an additional hour, and the mixture is then cooled, chloroform is added and the catalyst is filtered off. The chloroform solution is evaporated in vacuo. The residue is chromatographed on a silica gel dry-column and the product is distilled to give 3-(1,2- dimethylheptyl)-1-hydroxy-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran, b.p. 180-l83C. at 0.007 mm.
In like manner, the aromatized dibenzo[b,d]pyran may be obtained from 3-(l,2-dimethylheptyl)-1- hydroxy-6a, 7,8,l0a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran or from 3-(1,2-dimethylheptyl)-lhydroxy-6a, 7,10,l0a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
Substitution of an equivalent amount of 3-(1,2- dimethylheptyl)-1-hydroxy-6,6,9-trimethyl-6H- dibenzo[b,d]pyran into the procedure of Example 1 for 3-(1,2-dimethylheptyl)-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran gives the title compound.
EXAMPLE 8 2-(N,N-Dimethylaminomethyl)-3-(1.2-dimethylheptyl)-l-hydroxy-6a, 7,8,9,10,l0a-hexahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran A mixture of 2.9 g. (8.1 mmol.) of 3-(1,2- dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran in ml. of absolute ethanol and 10 percent palladium on carbon is hydrogenated at 48 p.s.i. and 25 until 8 mmol. of hydrogen is absorbed. After addition of a small amount ofchloroform the mixture is filtered, the solvent is evaporated and the residue is distilled to give 3-(l,2- dimethylheptyl)-1-hydroxy-6a,7,8,9,10,10ahexahydro-6,6,9-trimethyl-6l-l-dibenzo[b.d]pyran.
In like manner, the hexahydro dibenzo[b,d]pyran may be obtained from 3-(1,2-dimethylheptyl)-1- hydroxy-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran or from 3-(1,2-dimethylheptyl)-lhydroxy-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
Substitution of an equivalent amount of 3-(1,2- dimethylheptyl)-1-hydroxy-6a,7,8,9,10,10ahexahydro-6,6,9-trimethyl-6ll-dibenzo[b,d]pyran in the A procedure of Example 1 for 3-(1,2- dimethylheptyl)-l-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran gives the title compound.
EXAMPLE 9 2-(N,N-Dimethylaminomethyl)-3-(1,2- dimethyldecyl)-l-hydroxy-7,8.9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo-[b,dJpyran To the Grignard reagent prepared from 13.3 g. (0.56 mol.) of magnesium turnings and 123.9 g. (0.56 mol.) of 2-bromodecane in anhydrous ether, under nitrogen, is added with stirring a solution of 50.5 g. (0.28 mol.) of 3,S-dimethoxyacetophenone [J. Prakt. Chem. 107:104 (1924)] in 200 ml. of anhydrous tetrahydrofuran. After refluxing for 12 hours the mixture is quenched with 300 ml. of saturated aqueous ammonium chloride and extracted with ether. The extracts are washed with water, dried (MgSO and the solvent is removed to give 5-(l,2-dimethyl-1- hydroxydecyl)resorcinol dimethyl ether.
Dehydration by distillation from a few drops of 20 percent aqueous sulfuric acid gives a mixture of 5-(1,2- dimethyldec-l-enyl)resorcinol dimethyl ether and 5- (1-methylenyl-2-methyldecyl)resorcinol dimeth'yl ether which is hydrogenated over 10 percent palladium on carbon in absolute ethanol at 50 p.s.i. and 25 to give 5-(1,2-dimethyldecyl)-resorcinol dimethyl ether.
A solution of 30.6 g. (0.1 mol.) of 5-(1,2-dimethyldecyl)resorcinol dimethyl ether in 350 ml. of glacial acetic acid and 150 ml. of 48 percent hydrogen bromide is refluxed eight hours, then stirred at 25 for 12 hours. The reaction mixture is diluted with water and extracted three times with ether. The combined extracts are washed with saturated aqueous sodium bisulfite and saturated aqueous sodium bicarbonate, dried (MgSO concentrated and distilled to give (l,2- dimethyldecyl)resorcinol.
To a stirred solution of 3.9 g. (0.014 mol.) of 5-(1,2- dimethyldecyl)resorcinol and 2.57 g. (0.014 mol.) of 5-methyl-2-carbethoxycyclohexanone in 50 ml. of benzene is added a solution of2.17 g. (0.014 mol.) of phosphorus oxychloride in 5 ml. of benzene. After one hour the reaction mixture is refluxed for five minutes then allowed to stir at 25 for 24 hours. Water is then added and the mixture is refluxed for 15 minutes and ethyl acetate is added. The layers are separated and the organic phase is washed with 5 percent aqueous sodium bicarbonate, dried (MgSO and concentrated. The residue is triturated with a minimum amount of 40 percent aqueous sodium hydroxide. The precipitate which forms is filtered, washed with benzene and percent aqueous sodium hydroxide, acidified with dilute hydrochloric acid and extracted into benzene. The benzene solution is dried (MgSO and concentrated to give 3- 1 ,2-dimethyldecyl)-l-hydroxy-7,8,9,10-tetrahydro-9- methyl-6l-l-dibenzo[b,d]pyrone.
A solution of 3.0g. (7.6 mmol.) of the dibenzo[b,d]- pyrone in benzene is added to a stirred solution of 50 ml. (0.1 mol.) of a solution of methyl magnesium bromide in benzene-tetrahydrofuran under nitrogen. After refluxing for 18 hours the solution is'slowly poured with stirring onto 300 ml. of ice-water containing 40 ml. of concentrated hydrochloric acid. The cold mixture is extracted with ether and the organic phase is dried (MgSO and concentrated. Distillation of the residue gives 3-( l,2-dimethyldecyl)-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran.
Substitution of an equivalent amount of 3-(1 ,2- dimethyldecyl)-l-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 1 for 3-(l,2-dimethylheptyl)-1-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran gives the title compound.
EXAMPLE l0 2-(N,N-Dimethylaminomethyl)-3-dodecyl-l-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran To the Grignard reagent prepared from 18.3 g. (0.75 mol.) of magnesium turnings and 176.5 g. (0.75 mol.) of l-bromoundecane in anhydrous ether under nitrogen is added with stirring 40.8 g. (0.25 mol.) of 3,5-dimethoxybenzonitrile. The reaction mixture is refluxed for eight hours, cooled, poured onto a stirred 2N sulfuric acid-ice mixture and the solvent is evaporated. The remaining aqueous solution is stirred at 95 for one hour, cooled and extracted with ether. The extract is washed with water, dried (MgSO and concentrated to give a residue which is distilled to give 3,5- dimethoxyphenyl undecyl ketone.
To a solution of 41 .5 g. (0.74 mol.) of potassium hydroxide in 400 ml. of ethylene glycol is added 32.1 g. (0.1 mol.) of 3,5-dimethoxyphenyl undecyl ketone and 43 ml. of 85 percent hydrazine hydrate. The reaction mixture is refluxed for one hour, distilled up to 185, then refluxed an additional ten hours. The mixture is EXAMPLE 1 1 3-Decyl-2-(N,N-dimethylaminomethyl)-l-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran Substitution of an equivalent amount of 1- bromononane in the procedure of Example 10 followed by reduction and demethylation as described gives 5- decylresorcinol.
Condensation of equivalent amounts of 5- decylresorcinol and 5-methyl-2-carbethoxycyclohexanone followed by treatment with methyl magnesium bromide and subsequent cyclization as described in Example 9 gives 3-decyl-1-hydroxy-7,8,9,l0-tetrahydro- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran.
When an equivalent amount of 3-decyl-1-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran is substituted in the procedure of Example 1 for 3-(1,2-dimethy1heptyl)-l-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran, the title compound is obtained.
EXAMPLE 12 2-(N,N-Dimethylaminomethyl)-l-hydroxy-7,8,9,10- tetrahydro-3-(1,1,2-trimethylheptyl)-6,6,9-trimethyl- 6l-ldibenzo[b.d]pyran To 0.2 mol. of methyl magnesium bromide (2N in tetrahydrofuran-benzene), under nitrogen, is added 55.6 g. (0.2 mol.) of 2-(3,5-dimethoxyphenyl)-2- methyloct-3-one [J. Amer.. Chem. Soc. :664 (1948);
amounts of 5- Helv. Chim. Acta 521116 (1969)] in tetrahydrofuran.
After refluxing for 12 hours the mixture is quenched with saturated aqueous ammonium chloride and extracted with ether. The extracts are washed with water, dried (MgSO and the solvent is removed to give 5-(2- hydroxy-l l ,Z-trimethylheptyl)resorcinol dimethyl ether as an oil. A solution of 5.9 g. (0.020 mol.) of the carbinol in ether is allowed to react over a six hour period with a suspension of0.8 g. (0.020 mol.) of metallic potassium in 60 ml. of ether. Carbon disulfide (1.5 g.; 0.020 mol.) is added and the mixture is stirred for 30 minutes, then 2.8 g. (0.020 mol.) of methyl iodide is added and the reaction mixture is refluxed for six hours and left at 25 for 12 hours. The mixture is filtered and the filtrate is concentrated and distilled in vacuo. The distillate is dissolved in ethanol, refluxed with Raney nickel and redistilled to give a mixture of 5-(l,l,2-
S-methyI-Z-carbethoxycy-' EXAMPLE 13 2-(N,N-Dimethylaminomethyl)-3-(1-ethyl-2- methylheptyl)-l-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethy1-6l-l-dibenzo-[b,d]pyran Substitution of equivalent amounts of 3,5- dimethoxyphenyl ethyl ketone and 2-bromoheptane in the procedure of Example 9 for 3,5- dimethoxyacetophenone and 2-bromodecane followed by dehydration, hydrogenation, and removal of the protective groups as described gives 5-(1-ethyl-2- methylheptyl)resorcinol.
Condensation of equivalent amounts of 5-(l-ethyl- Z-methylheptyl)resorcinol and 5-methyl-2-carbethoxycyclohexanone followed by treatment with methyl magnesium bromide and subsequent cyclization as described in Example 9 gives 3-(1-ethyl-2-methylheptyl)- 1 -hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethy1-6H- dibenzo[b,d]pyran.
When an equivalent amount of 3-(1-ethyl-2- methylheptyl)-1-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6l-l-dibenzo[b,d]pyran is substituted in the procedure of Example 1 for 3-(l,2-dimethylheptyl)-lhydrxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran, the title compound is obtained.
EXAMPLE l4 3-(1,2-Diethylheptyl)-2 (N,N-dimethylaminomethyl)- 1 -hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethy1-6H- dibenzo-[b,d]pyran Substitution of equivalent amounts of 3,5- dimethoxyphenyl ethyl ketone and 3-bromooctane in the procedure of Example 9 for 3,5- dimethoxyacetophenone and Z-bromodecane followed by dehydration, hydrogenation and removal of the protective groups as described gives 5-(1,2-diethylhepty1)- resorcino].
Condensation of equivalent amounts of 5-(1,2- diethylheptyl)resorcino1 and S-rnethyl-Z-carbethoxycyclohexanone followed by treatment with methyl magnesium bromide and subsequent cyclization as described in Example 9 gives 3-(l,2-diethy1heptyl)-1- hydroxy-7,8 ,9, l 0-tetrahydro-6 ,6,9-trimethyl-6H- dibenzo[b,d]pyran.
When an equivalent amount of 3-(l,2-diethy1- heptyl)-1-hydroxy-7,8,9,10-tetrahydro 6,6,9- trimethyl-6H-dibenzo[b,d]pyran is substituted in the procedure of Example 1 for 3-(1,2-dimethy1heptyl)- 1 -hydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-61-1- dibenzo[b,d]pyran, the title compound is obtained.
EXAMPLE 15 Substitution of an equivalent amount of a 3-alkyl-lhydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran listed below:
1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-3- pentyl-6H-dibenz0[b,d]pyran 3-heptyl-1-hydroxy-7,8,9,l0tetrahydro-6.6.9- trimethyl-6-H-dibenzo[b,d]pyran l-hydroxy-7,8,9,10-tetrahydro-3-(1-methylheptyl)- 6,6,9-trimethyl-6- H-dibenzo[b,d]pyran in the procedure of Example 1 for 3-(1,2-dimethy1heptyl)-1- hydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran gives the following 2-(N,N- 'dimethylaminomethyl) dibenzo[b,d]pyrans:
2-(N,N dimethylaminomethyl)-1-hydroxy-7,8,9,l0- tetrahydro-6,6,9-trimethyl-3-pentyl-6H- dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-3-heptyl-l-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-1-hydroXy-7,8,9,l0- tetrahydro-3-(1methylheptyl)-6,6,9-trimethyl-6H- dibenzo-[-b,d]pyran.
EXAMPLE 16 When a 3-alkyl-1-hydroxy-7,8,9,1()-tetrahydro-6,6,9- trimethyl-oH-dibenzo[b,d]pyran listed below:
1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-3- pentyl-6H-dibenzo[b,d]pyran 3-decyl-1-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran 1-hydroxy-7,8,9,10-tetrahydro-3-( 1,1 ,2- trimethylheptyl)-6,6,9-trimethyl-6H- dibenzo[b,d]pyran 3-( 1-ethyl-2-methylheptyl)-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6l-I-dibenzo[b,d]pyran 'l-hydroxy-7,8,9,l0-tetrahydro-3-(1-methylheptyl)- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran 3-(1,2-dimethyldecyl)-1-hydroxy-'/i,8,9,l0- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran is treated with piperidine according to the procedure of Example 1, the following 3-alkyl-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-2-piperidinomethyl-6H- dibenzo[b,d]pyrans are obtained:
1-hydroxy 7,8,9,1O-tetrahydro-6,6,9-trimethyl-3 pentyl-Z-piperidinomethyl-6H-dibenzo[b,d]pyran 3-decy1-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-2-piperidinomethyl-H-dibenzo[b,d]pyran 1-hydroxy-7,8,9,10-tetrahydr0-3-(1,1,2- trimethylheptyl)-6,6,9-trimethyl-2-piperidinomethyl- 6H-dibenzo[b,d]pyran 3-(1-ethyl-2-methylheptyl)-1-hydroxy-7,8,9,10- tetrahydro -6,6,9-t rimethyl-Z-piperidinomethyl-6H- dibenzo[b,d]pyran l-hydroxy-7,8,9,10-tetrahydro-3-(1-methylheptyl)- 6,6,9-trimethyl 2-piperidinomethyl-6H- dibenzo[b,d]pyran 3-( 1,2-dimethyldecyl)-1-hydroxy-7,8,9,l0- tetrahydro-6,6,9-trimethyl-2-piperidinomethyl-6H- dibenzo[b,d]pyran.
Likewise, reaction of a 3-alkyl-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran listed above with an amine listed in Example 2 gives the corresponding 3-alkyl-2-aminomethy1-l-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyrans.
l3 EXAMPLE 17 When an equivalent amount of a 3-alkyl-1-hydroxy- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran listed in Example 16 is substituted in the procedure of Example 3 for 3-(l,2- dimethylheptyl)-l-hydroxy-7,8,9,lO-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran, the following 2-(N- methylaminomethyl)dibenzo[b,d]pyrans are obtained:
l-hydroxy-7,8,9,IO-tetrahydro-Z-(N- methylaminomethyl)-6,6,9-trimethyl-3-pentyl-6l-l- 3-decyll -hydrxy-7,8 ,9,10-tetrahydro-2-(N- methylaminomethyl -6,6,9-trimethyl-6H- dibenzo[b,d]pyran 1-hydroxy-7,8,9, IO-tetrahydro-Z-(N- methylaminomethyl)-3-(1,1,Z-trimethylheptyl)-6,6,9- trimethyl-6l-l-dibenzo[b,d]pyran 3-( 1-ethyl-2-methylheptyl)-1-hydroxy-7,8,9,10- tetrahydro-2-(N-methylaminomethyl )-6 ,6,9-trimethyl- 6l-l-dibenzo[b,d]pyran l-hydroxy-7,8,9, l O-tetrahydro-2-( N- methylaminomethyl)-3-( l-methylheptyl)-6,6,9- trimethyl-6H-dibenzo[b,d]pyran 3-(1,2-dimethyldecyl)-1-hydroxy-7,8,9,10- tetrahydro-2-( N-methylaminomethyl )-6,6,9-trimethyl- 6ll-dibenzo[b,d]pyran.
EXAMPLE 18 EXAMPLE 19 When equivalent amounts of l,2-dimethylheptyl)- resorcinol and 4-methyl-2-carbethoxycyclohexanone are condensed according to the procedure described in Example 9 and the intermediate dibenzo[b,d]pyrone is treated with methyl magnesium bromide and the product cyclized, 3-(l,2-dimethylheptyl)-l-hydroxy- 7,8,9,lO-tetrahydro-6,6,8-trimethyl-6ll-ldibenzo[b,d]pyran is obtained.
Substitution of an equivalent amount of 3-(1,2- dimethylheptyl)-l-hydroxy-7,8,9,l0-tetrahydro-6,6,8- trimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 1 for 3-(1,2-dimethylheptyl)-l-hydroxy- 7,8,9,l0-tetrahydro-6,6,9 trimethyl-6H- dibenzo[b,d]pyran gives 2-(N,N- dimethylaminomethyl)-3-( l ,2-dimethylheptyl)- l hydroxy-7,8,9,10-tetrahydro-6,6,8-trimethyl-6H- dibenzo-[b,d]pyran.
Similarly, condensation of 5-(l,2-dimethylheptyl)resorcinol and 3-methyl-2-carbethoxycyclohexanone as described in Example 9, treatment of the dibenzo[b,d]pyrone with methyl magnesium bromide, subsequent cyclization and reaction of the dibenzo[b,d]pyran with dimethylamine and paraformaldehyde as described in Example 1 gives 2-(N.N- dimethylaminomethyl)-3-( l ,Z-dimethylheptyl l hydroxy-7,8,9,lO-tetrahydrol6,6,7-trimethyl-6H- dibenzo[b,d]pyran.
In like manner, when 5-(l,2-dimethylheptyl)- resorcinol is condensed with 6-methyl-2-carbethoxycyclohexanone and the dibenzo[b,d]pyrone is treated with methyl magnesium bromide and the product cyclized as previously described followed by reaction of the dibenzo-[b,d]pyran with dimethylamine and paraformaldehyde as described in Example 1, 2-(N,N- dimethylaminomethyl)-3-( l ,2-dimethylheptyl)-lhydroxy-7,8,9,lO-tetrahydro-6,6,l0-trimethyl-6H- dibenzo[b,d]pyran is obtained.
EXAMPLE 20 2-(N,N-Dimethylaminomethyl)-3-(1,2- dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6- dimethyl-6H-dibenzo[b,dl-pyran 3-( l ,2-Dimethylheptyl)- l -hydroxy-7,8,9,l0- tetrahydro-6,6-dimethyl-6l-l-dibenzo[b,d]pyran is prepared by reaction of equivalent amounts of 5-(l,2- dimethyl-heptyl)resorcinol and 2-carbethoxycyclohexanone as described in Example 9.
Treatment of 3-( l ,2-dimethylheptyl)-l -hydroxy- 7,8,9,l0-tetrahydro-6,6,-dimethyl-6H- dibenzo[b,d]pyran with dimethylamine and paraformaldehyde according to the procedure of Example 1 gives the title compound.
EXAMPLE 21 2-(N,N-Dimethylaminomethyl)-3-(1,2-
.dimethylheptyl )-9-ethyll -hydroxy-7,8 ,9 l 0- tetrahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran Condensation of equivalent amounts of 5-(l,2- dimethylheptyl)resorcinol and 5-ethyl-2-carbethoxycyclohexanone followed by treatment of the dibenzo[b,d]pyrone with methyl magnesium bromide and subsequent cyclization as described in Example 9 gives 3-( l ,Z-dimethylheptyl)-9-ethyll -hydroxy-7,8,9, l 0- tetrahydr0-6,6-dimethyl-6l-l-dibenzo[b,d]pyran.
Substitution of an equivalent amount of 3-(l,2- dimethylheptyl)-9-ethyl-l-hydroxy-7,8,9,10- tetrahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 1 for 3-(l,2-dimethylheptyl)-l' hydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran gives the title compound.
EXAMPLE 22 2-(N,N-Dimethylaminomethyl)-3-( l ,2- dimethylheptyl)-6,6-diethyl-1-hydroxy-7,8,9,l0- tetrahydro-9-methyl-6H-dibenzo[b,d]pyran When 7 ,8 ,9 l 0-tetrahydro-9-methyl-6lH-dibenzo[b,d] pyrone is treated with ethyl magnesium bromide and subse quently cyclized as described in Example 9, 3-(l,2- dimethylheptyl)-6,6-diethyl-l-hydroxy-7,8,9,10- tetrahydro-9-methyl-6l-l-dibenzo[b,d]pyran is tained.
3-(1,2-dimethylheptyl)-1-hydroxy- 19 7 EXAMPLE 31 dure of Example 7 for 3-(l,2-dimethylheptyl)-lhydroxy-7,8,9,lO-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran gives the following aromatic dibenzo[b,d]pyrans:
l-hydroxy-6,6,9-trimethyl-3-pentyl-6H- dibenzo[b,d]pyran 3-decyl-l-hydroxy-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran l-hydroxy-3-( l,l,2-trimethylheptyl)-6,6,9-trimethyl- 6l-l-dibenzo[b,d]pyran 3-( i-ethyl-2-methylheptyl)-1-hydroxy-6,6,9- trimethyl-6H-dibenzo[b,d]pyran l-hydroxy-3-( l-methylheptyl)-6,6,9-trimethyl-6H- dibenzo[b,d]pyran 3-(1,2-dimethyldecyl)-1-hydroxy-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran.
When a 3-alkyl-l-hydroxy-6,6,9-trimethyl-6H- dibenzo[b,d]pyran listed above is substituted in the procedure of Example I for 3-(l,2-dimethylheptyl)-lhydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran, the following 2-(N,N- dimethylaminomethyl)dibenzo[b,d]pyrans are obtained:
2-(N,N-dimethylaminomethyl)l-hydroxy-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran 3-decyl-2-(N,N-dimethylaminomethyl)-l-hydroxy- 6,6,9-trimethyl-6l-l-dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-1-hydroxy-3-( 1,1,2- trimethylheptyl)-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-3-( l-ethyl-2-, methylheptyl)-l-hydroxy-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-l-hydroxy-3-( 1- methylheptyl)-6,6,9-trimethyl-6-l-l-dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-3-(1,2- dimethyldecyl)-l-hydroxy-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
EXAMPLE 32 3-(1,2-Dimethylheptyl)-l-hydroxy-2-(N- methylaminomethyl)-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran is prepared by substitution of an equivalent amount of 3-( l,2-dimethylheptyl)-lhydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 3 for 3-(l,2-dimethylheptyl)-lhydroxy-7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
Similarly, substitution of an equivalent amount of 3- (l,Z-dimethylheptvll-l-hydroxy-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran in the procedure of Example 4 for 3-( l ,2-dimethylheptyl)-1-hydroxy-7,8,9,l0- tetrahydro-6,6,9-trimethyl-6l-l-dibenzo[b,d]pyran gives 2-aminomethyl-3-(1,Z-dimethylheptyl)-6,6,9- trimethyl-6H-dibenzo[b,d]pyran.
EXAMPLE 33 When an equivalent amount of a 3-alkyl-l-hydroxy- 7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran listed in Example 16 is substituted in the procedure of Example 8 for 3-(l,2- dimethylheptyl)-1-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran, the follow 20 6a,7,8,9,l0,10a-hexahydro dibenzo[b,d]pyrans are obtained:
2-(N,N-dimethylaminomethyl)-l-hydroxy- 6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl- 6H-dibenzo[b,d]-pyran 3-decyl-2-(N,N-dimethylaminomethyl)-l-hydroxy- 6a,7,8,9,l0,10a-hexahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-l-hydroxy- 6a,7,8,9,l0,l0a-hexahydro-3-( 1,1 ,2-trimethylhcptyl)- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-3-(l-ethyl-Z- methylheptyl)-l-hydroxy-6a,7,8,9,l0,lOu-hcxahydro- 6,6,9-trimethyl-6H-dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-l-hydroxy- 6a,7,8,9,l0,10a-hexahydro-3-( l-methylheptyl)-6,6,9- trimethyl-6H-dibenzo[b,d]pyran 2-(N,N-dimethylaminomethyl)-3-(1,2- dimethyldecyl)-l-hydroxy-6a,7,8,9,10,10a-hexahydro- 6,6,9-trimethyl-6l-l-dibenzo[b,d]pyran.
EXAMPLE 34 3-( l ,2-Dimethylheptyl)-l-hydroxy6a,7,8,9,10,10ahexahydro-2-(N-methylaminomethyl)-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran is prepared by substitution of an equivalent amount of 3-(1,2-dimethylheptyl)-lhydroxy-6a,7,8,9,l0,10a-hexahydro-6,6,9-trimethyl- 6l-l-dibenzo[b,d]pyran in the procedure of Example 3 for 3-(1,2-dimethylheptyl)-1-hydroxy-7,8,9,10- tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran.
Similarly, substitution of an equivalent amount of 3- l,Z-dimethylheptyl-l-hydroxy-6a,7,8,9,10,10ahexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran in the procedure of Example 4 for 3-(l,2- dimethylheptyl)-1-hydroxy-7,8,9,lO-tetrahydro-6,6,9- trimethyl-6l-l-dibenzo[b,dlpyran gives 2-aminomethyl- 3-(l,2-dimethylheptyl)-1-hydroxy-6a,7,8,9,l0,10ahexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran.
EXAMPLE 35 1-Acetoxy-2-(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-6,6,9-trimethyl-7,8,9,10-tetrahydro- 6l-l-dibenzo[b,d]pyran A solution of 1.2 g. of l-hydroxy-2-(N,N- dimethylaminomethyl)-3-(1,Z-dimethylheptyl)-6,6,9- trimethyl-7,8,9,10-tetrahydro-6l-l-dibenzo[b,dJpyran in 20 ml. of acetic anhydride containing 0.5 g. of sodium acetate is refluxed for five hours. The excess anhydride is evaporated in vacuo and the residue is dissolved in water and extracted with ether. The extract is washed with water until neutral, then dried and evaporated to give a residue, which is chromatographed on a silica gel dry-column to give the title compound.
EXAMPLE 36 By the procedure of Example 35, using propionic anhydride in place of acetic anhydride, the product is 2- (N,N-dimeth-ylaminomethyl)-3-( 1 ,Z-dimethylheptyl 7,8,9,10-tetrahydro-6,6,9-trimethyl-1-propionyloxy- 6H-dibenzo[b,d]pyran.
Similarly, using n-butyric anhydride, the product is l-n-butyryloxy-2-(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-7,8,9,l0-tetrahydro-6,6,9-trimethyl- 6H-dibenzo[b,d]pyran.
By the same procedure, using n-valeric anhydride, the product is 2-(N,N-dimethylaminomethyl)-3-(1,2-
21 dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethylln-valeryloxy-6H-dibenzo[b,d ]pyran.
EXAMPLE 37 EXAMPLE 38 Substitution of an equivalent amount of 3-( l ,2- dimethylheptyl)-l-hydroxy-7,8,9,IO-tetrahydro-Z-(N- methyl-N-benzylaminomethyl)-6,6,9-trimethyl-6H- dibenzo[b,d]pyran in the procedure of Example 35 for 2-(N,Ndimethylaminomethyl)-3-(1,2- dimethylheptyl)-l-hydroxy-7,8,9,lO-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran gives 1-acetoxy-3- (1,2-dimethylheptyl)-7,8,9, l O-tetrahydro-Z-(N- methyl-N-benzylaminomethyl)-6,6,9-trimethyl-6H- dibenzo[b,d]pyran which is hydrogenolyzed over palladium on carbon in glacial acetic acid to give l-acetoxy- 3-( l ,Z-dimethylheptyl)-7,8,9, l O-tetrahydro-Z-(N- methylaminomethyl)-6,6,9-trimethyl-6H- dibenzo[b,d]pyran.
In a similar manner, l-propionyloxy, l-n-butyryloxy and l-n-valeryloxy-3-(l,2-dimethylheptyl)-7,8,9,l0- tetrahydro-2-(N-methylaminomethyl)-6,6,9-trimethyl 6H-dibenzo[b,d]pyran are prepared.
EXAMPLE 39 Substitution of an equivalent amount of 2-(N,N- dibenzylaminomethyl)-3-( 1 ,2-dimethylheptyl)-lhydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6l-ldibenzo[b,d]pyran in the procedure of Example 35 for 2-(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-l-hydroxy-7,8,9,lO-tetrahydro-6,6,9- trimethyl-6l-l-dibenzo[b,d]pyran gives l-acetoxy-Z- (N,N-dibenzylaminomethyl )-3-( 1 ,2-dimethylheptyl)- 7,8,9,10-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran which is hydrogenolyzed over palladium on carbon in glacial acetic acid to give l-acetoxy- 2-aminomethyl-3-( 1,2-dimethylheptyl)7,8,9, l tetrahydro6,6,9-trimethyl-6H-dibenzo[b,d]pyran.
22 In like manner, l-propionyloxy, l-n-butyryloxy and l-n-valeryloxy-2-aminomethyl-3-( l ,Z-dimethylheptyl 7,8,9,l0-tetrahydro-6,6,9-trimethyl-6H- dibenzo[b,d]pyran are prepared.
What is claimed is: l. A compound of the formula:
in which:
ring A is a benzene ring, a cyclohexane ring or a cyclohexene ring with the double bond being at position 6a-10a, 8 or 9;
R is hydrogen, methyl or ethyl;
R is hydrogen or lower alkanoyl of from two to five carbon atoms;
R is a saturated hydrocarbon chain optionally branched with from one to three alkyl groups, each group consisting of one or two carbon atoms, with R containing a total of from five to twelve carbon atoms;
R; and R are hydrogen or lower alkyl of from one to four carbon atoms or are joined together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine ring; and
R is methyl or ethyl.
2. A compound as claimed in claim 11 where ring A is a cyclohexene ring with the double bond at the 6a-l0a position and R and R are lower alkyl of from one to four carbon atoms or are joined together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine ring.
3. A compound as claimed in claim 2 where R is methyl in the 9-position, R is hydrogen or acetyl, R is a saturated hydrocarbon chain optionally branched with from one to three methyl groups, with R containing a total of from five to twelve carbon atoms and R R and R are methyl.
4. A compound as claimed in claim 3 being the compound 2(N,N-dimethylaminomethyl)-3-(1,2- dimethylheptyl)-1-hydroxy-7,8,9,l0-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran.
P0405) UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,856,820 v Dated December 24 1914 InventoflQW It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
' Column 4, line 11, "6a, 7 mun-mu dro" llwtlld road 6a,7,10,10o-tetrahydro and 6:,7, ,IOa-tetrakydro Column 7, line 54, "200 3." should read 2.0 g.
Golan 14, line 11 "tetrahydro16 ,6,7"- should read tetrahydr ,6,7
Colunn 18 line 37 "6 ,6-d1etky1- should read 6,6-d1etn 1-1- Column 19, 11 68, "follow" should read following Signed and sealed this 1st day of April 1.975.
r- 8 Lil) [it t e St 2 C I'L'XRSI'LAL L BAND.
RUTH C. 21.2303. ommissioner of Patents Attesting Officer and Trademarks

Claims (4)

1. A COMPOUND OF THE FORMULA:
2. A compound as claimed in claim 1 where ring A is a cyclohexene ring with the double bond at the 6a-10a position and R4 and R5 are lower alkyl of from one to four carbon atoms or are joined together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine ring.
3. A compound as claimed in claim 2 where R1 is methyl in the 9-position, R2 is hydrogen or acetyl, R3 is a saturated hydrocarbon chain optionally branched with from one to three methyl groups, with R3 containing a total of from five to twelve carbon atoms and R4, R5 and R6 are methyl.
4. A compound as claimed in claim 3 being the compound 2(N,N-dimethylaminomethyl)-3-(1,2-dimethylheptyl)-1-hydroxy-7,8,9,10 -tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran.
US00380326A 1973-07-18 1973-07-18 2-AMINOMETHYL DIBENZO (b,d) PYRANS Expired - Lifetime US3856820A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00380326A US3856820A (en) 1973-07-18 1973-07-18 2-AMINOMETHYL DIBENZO (b,d) PYRANS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00380326A US3856820A (en) 1973-07-18 1973-07-18 2-AMINOMETHYL DIBENZO (b,d) PYRANS

Publications (1)

Publication Number Publication Date
US3856820A true US3856820A (en) 1974-12-24

Family

ID=23500758

Family Applications (1)

Application Number Title Priority Date Filing Date
US00380326A Expired - Lifetime US3856820A (en) 1973-07-18 1973-07-18 2-AMINOMETHYL DIBENZO (b,d) PYRANS

Country Status (1)

Country Link
US (1) US3856820A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102902A (en) * 1976-11-10 1978-07-25 Eli Lilly And Company Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor
US4176233A (en) * 1976-11-10 1979-11-27 Eli Lilly And Company Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor
FR2432498A1 (en) * 1978-08-02 1980-02-29 Yissum Res Dev Co NEW PINENE DERIVATIVES AND THEIR PREPARATION
US4721815A (en) * 1986-12-22 1988-01-26 Amoco Corporation Preparation of substituted benzophenones
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20040138315A1 (en) * 2000-09-28 2004-07-15 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20040242870A1 (en) * 2000-09-28 2004-12-02 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US7105685B2 (en) * 1999-03-22 2006-09-12 Travis Craig R Cannabinol derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654312A (en) * 1970-05-21 1972-04-04 Little Inc A Novel 6-oxo-7 8 9 10-tetrahydro-6h-dibenzo(b d)pyrans

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654312A (en) * 1970-05-21 1972-04-04 Little Inc A Novel 6-oxo-7 8 9 10-tetrahydro-6h-dibenzo(b d)pyrans

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102902A (en) * 1976-11-10 1978-07-25 Eli Lilly And Company Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor
US4176233A (en) * 1976-11-10 1979-11-27 Eli Lilly And Company Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor
FR2432498A1 (en) * 1978-08-02 1980-02-29 Yissum Res Dev Co NEW PINENE DERIVATIVES AND THEIR PREPARATION
US4721815A (en) * 1986-12-22 1988-01-26 Amoco Corporation Preparation of substituted benzophenones
US5498419A (en) * 1994-06-03 1996-03-12 Pars; Harry G. Fumarate salt of 4-(diethyl-3-(1-methyloctyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol, 4-(diethyl-amino) butyric
US7105685B2 (en) * 1999-03-22 2006-09-12 Travis Craig R Cannabinol derivatives
US20040138315A1 (en) * 2000-09-28 2004-07-15 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20040242870A1 (en) * 2000-09-28 2004-12-02 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use

Similar Documents

Publication Publication Date Title
US3507885A (en) 3-alkyl-6h-dibenzo(b,d)pyrans
US4188495A (en) 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
US3886184A (en) Aminodibenzo(b,d)pyrans
Osyanin et al. Cycloaddition reactions of o-quinone methides with polarized olefins
US3856820A (en) 2-AMINOMETHYL DIBENZO (b,d) PYRANS
US4143139A (en) 9-Hydroxydibenzo[b,d]pyrans and intermediates
Razdan The total synthesis of cannabinoids
US3799946A (en) Dibenzo(b,d)pyran compounds
US3856821A (en) ALKOXY DIBENZO (b,d) PYRANS
US3856822A (en) 3-alkenyl dibenzo (b,d)pyrans
US3931232A (en) 3-Alkyl xanthene compounds
Bandaranayake et al. 3-Hydroxy-3-methyl-1, 1-dimethoxybutane, a new reagent for dimethylchromenylation: synthesis of lonchocarpin, jacareubin, evodionol methyl ether, and other chromens
US4140701A (en) 2,6-Methano-2H-1-benzoxocins
US4243674A (en) 9-Hydroxydibenzo[b,d]pyrans and intermediates therefore
Bergel et al. 257. Studies on vitamin E. Part IV. Synthetic experiments in the coumaran and chroman series. The structure of the tocopherols
Irie et al. The total synthesis of (±)-ochotensine and related compounds
US4118559A (en) 9-Hydroxyhexahydrodibenzo[O,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo[b,d]pyrans and intermediates therefor
ISHII et al. Total synthesis of chelerythrine, a benzo [c] phenanthridine alkaloid
US4270005A (en) 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor
US3798240A (en) 3-(hydroxymethyl)chromones
US3484448A (en) 2-(4-substituted phenyl)-3-lower alkyl-1,4-benzodioxane derivatives
Walker Podophyllotoxin Studies. Reductive Methods in the Synthesis of Tetralin Lactones from α-Tetralone Derivatives
US3856823A (en) DIBENZO (b,d) PYRANS
Singh et al. Antineoplastic agents. 166. Isolation, structure, and synthesis of combretastatin C-1
Leaf et al. 31. Cannabis indica. Part IX. The isolation of 3′: 4′: 5′: 6′-tetrahydrodibenzopyran derivates from pulegone–orcinol and pulegone–olivetol condensation products. Synthesis of d-tetrahydrocannabinol

Legal Events

Date Code Title Description
AS Assignment

Owner name: SMITHKLINE BECKMAN CORPORATION

Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769

Effective date: 19820304

Owner name: SMITHKLINE BECKMAN CORPORATION, PENNSYLVANIA

Free format text: CHANGE OF NAME;ASSIGNOR:SMITHKLINE CORPORATION;REEL/FRAME:004080/0769

Effective date: 19820304